3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Melanoma
11
Carcinoma, Non-Small-Cell Lung
7
Pancreatic Neoplasms
5
Triple Negative Breast Neoplasms
4
Neoplasms
4
Sarcoma
3
Neoplasm Metastasis
3
Head and Neck Neoplasms
3
Lymphoma
2
Liver Neoplasms
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Multiple Myeloma
1
Metastatic Pancreatic Ductal Adenocarcinoma
1
Mesothelioma
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Interventions
Cetuximab
4
Radiosurgery
3
Nivolumab
3
Ipilimumab
3
pembrolizumab
2
Vorinostat
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Magnetic Resonance Spectroscopy
2
Lapatinib
2
Dasatinib
2
Cisplatin
2
CTLA-4 Antigen
2
Bevacizumab
2
temsirolimus
1
ispinesib
1
eribulin
1
dehydroftorafur
1
apalutamide
1
amivantamab
1
alectinib
1
Specimen Handling
1
Sorafenib
1
Sirolimus
1
Platinum
1
Pilocarpine
1
Pemetrexed
1
Oral Hygiene
1
NVP-BKM120
1
Moxibustion
1
MK 2206
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Salivary Gland Neoplasms
×
spartalizumab
×
Clear all
No trials found.